A drug-biomarker interaction model to predict the key targets of Scutellaria barbata D. Don in adverse-risk acute myeloid leukaemia.

Molecular Diversity
Teng WangRui-Rong Xu

Abstract

A poor prognosis, relapse and resistance are burning issues during adverse-risk acute myeloid leukaemia (AML) treatment. As a natural medicine, Scutellaria barbata D. Don (SBD) has shown impressive antitumour activity in various cancers. Thus, SBD may become a potential drug in adverse-risk AML treatment. This study aimed to screen the key targets of SBD in adverse-risk AML using the drug-biomarker interaction model through bioinformatics and network pharmacology methods. First, the adverse-risk AML-related critical biomarkers and targets of SBD active ingredient were obtained from The Cancer Genome Atlas database and several pharmacophore matching databases. Next, the protein-protein interaction network was constructed, and topological analysis and pathway enrichment were used to screen key targets and main pathways of intervention of SBD in adverse-risk AML. Finally, molecular docking was implemented for key target verification. The results suggest that luteolin and quercetin are the main active components of SBD against adverse-risk AML, and affected drug resistance, apoptosis, immune regulation and angiogenesis through the core targets AKT1, MAPK1, IL6, EGFR, SRC, VEGFA and TP53. We hope the proposed drug-biomarker interact...Continue Reading

References

Nov 2, 2002·Blood·Muneo NumasakiMichael T Lotze
Jan 10, 2003·Nucleic Acids Research·Christian von MeringBerend Snel
Aug 3, 2004·Nature Reviews. Drug Discovery·Ismail Kola, John Landis
Sep 17, 2004·Clinica Chimica Acta; International Journal of Clinical Chemistry·Yun-Yi ChaSung-Hoon Kim
Aug 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Guido MarcucciClara D Bloomfield
Nov 18, 2006·Breast Cancer Research and Treatment·Hope RugoDebu Tripathy
Jan 5, 2007·Annual Review of Immunology·Casey T WeaverLaurie E Harrington
Mar 27, 2007·Advances in Immunology·Nagahiro MinatoMasakazu Hattori
Apr 17, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Benjamin S Braun, Kevin Shannon
Dec 26, 2008·World Journal of Gastroenterology : WJG·Zhi-Jun DaiLing-Qin Song
Sep 5, 2009·Bioinformatics·Giovanni ScardoniCarlo Laudanna
Dec 5, 2009·Best Practice & Research. Clinical Haematology·Richard M Stone
Jan 8, 2010·Breast Cancer Research and Treatment·Alejandra T PerezCharles L Shapiro
Jan 15, 2011·The FEBS Journal·Petrus J W NaudéUlrich L M Eisel
Mar 31, 2011·Nature Reviews. Clinical Oncology·Lisa Hutchinson, Rebecca Kirk
Jun 24, 2011·Journal of Applied Genetics·Chandra Shekhar PareekAndrzej Tretyn
Sep 29, 2011·Drug Metabolism Reviews·Antje HavemeyerBernd Clement
Feb 22, 2012·Growth Factors·Hiu Kiu, Sandra E Nicholson
Mar 30, 2012·Omics : a Journal of Integrative Biology·Guangchuang YuQing-Yu He
Jun 26, 2012·Drug Discovery Today·Asfar S AzmiFazlul H Sarkar
Jul 28, 2012·International Journal of Molecular Sciences·Xue XuYang Ling
Sep 14, 2012·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Hitomi NakazawaNaoyuki Inagaki
Jan 3, 2013·Cancer Science·Tomoyoshi Soga
Feb 16, 2013·Bioorganic & Medicinal Chemistry Letters·Young-Won ChinSun-Young Han
Apr 27, 2013·The Journal of Nutritional Biochemistry·Chun-Yin HuangMing-Fen Lee
Oct 5, 2013·Journal of Enzyme Inhibition and Medicinal Chemistry·Kalyan K Sethi, Saurabh M Verma
Mar 22, 2014·International Journal of Molecular Medicine·Min Chul KimByung Joo Kim
Apr 17, 2014·Journal of Cheminformatics·Jinlong RuLing Yang
May 6, 2014·Nucleic Acids Research·David GfellerVincent Zoete
Jun 5, 2014·International Journal of Cancer. Journal International Du Cancer·Gernot PolierMin Li-Weber

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.